Question 1

What is POLATUZUMAB VEDOTIN used for?

Accepted Answer

POLATUZUMAB VEDOTIN (brand name POLIVY) is a Other indicated for 1 INDICATIONS AND USAGE POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: in combination with a rituximab product, cyclophosphamide, doxorubicin.

Question 2

How does POLATUZUMAB VEDOTIN work?

Accepted Answer

POLATUZUMAB VEDOTIN works through the following mechanism: 12.1 Mechanism of Action Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate with activity against dividing B cells. The small molecule, MMAE, is an anti-mitotic agent covalently attached to the antibody via a cleavable linker. The monoclonal antibody binds to CD79b, a B-cell specific surface protein, which is a component of the B-cell receptor. Upon binding CD79b, polatuzumab vedotin-piiq is internalized, and the linker is cleaved by lysosomal proteases to enable intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis..

Question 3

What are the most common side effects of POLATUZUMAB VEDOTIN?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for POLATUZUMAB VEDOTIN. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is POLATUZUMAB VEDOTIN the same as POLIVY?

Accepted Answer

POLIVY is a brand name for POLATUZUMAB VEDOTIN. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

POLATUZUMAB VEDOTIN

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations